重症患者凝血酶原复合物合理应用中国专家共识

宋景春; 王岗; 房云海; 吴海鹰; 尹海燕; 张进华; 柯路; 丁仁彧; 周洲; 中国医药教育协会血栓与止血危重病专业委员会; 全军重症医学专业委员会; 中国研究型医院学会血栓与止血专业委员会

doi:10.11855/j.issn.0577-7402.1079.2023.1103

您当前的位置：

首页 >

文章列表页 >

重症患者凝血酶原复合物合理应用中国专家共识

指南与共识 | 更新时间：2024-01-04

- 重症患者凝血酶原复合物合理应用中国专家共识
- Chinese expert consensus on the rational use of prothrombin complex concentrate in critically ill patients
- 解放军医学杂志 2023年48卷第12期页码：1359-1369
- 作者机构：
  
  1.解放军联勤保障部队第908医院重症医学科，江西南昌　330002
  2.西安交通大学第二附属医院重症医学科，陕西西安　710004
  3.山东省血液中心血友病诊疗中心，山东济南　250013
  4.昆明医科大学第一附属医院急诊科，云南昆明　650032
  5.暨南大学附属第一医院重症医学科，广东广州　510630
  6.福建省妇幼保健院药学科，福建福州　350005
  7.东部战区总医院重症医学科，江苏南京　210002
  8.中国医科大学附属第一医院重症医学科，辽宁沈阳　110001
  9.中国医学科学院阜外医院检验科，北京　100037
- 作者简介：
  
  宋景春，E-mail：songjingchun@126.com
- 基金信息：
- DOI：10.11855/j.issn.0577-7402.1079.2023.1103
  中图分类号：
扫描看全文
宋景春, 王岗, 房云海, 等. 重症患者凝血酶原复合物合理应用中国专家共识[J]. 解放军医学杂志, 2023, 48(12): 1359-1369.

Song Jing-Chun,Wang Gang,Fang Yun-Hai,et al.Chinese expert consensus on the rational use of prothrombin complex concentrate in critically ill patients[J].Medical Journal of Chinese People′s Liberation Army,2023,48(12):1359-1369.
宋景春, 王岗, 房云海, 等. 重症患者凝血酶原复合物合理应用中国专家共识[J]. 解放军医学杂志, 2023, 48(12): 1359-1369. DOI： 10.11855/j.issn.0577-7402.1079.2023.1103.

Song Jing-Chun,Wang Gang,Fang Yun-Hai,et al.Chinese expert consensus on the rational use of prothrombin complex concentrate in critically ill patients[J].Medical Journal of Chinese People′s Liberation Army,2023,48(12):1359-1369. DOI： 10.11855/j.issn.0577-7402.1079.2023.1103.

摘要

凝血酶原复合物(PCC)是以维生素K依赖性凝血因子为主要成分的血液制品。虽然PCC已在临床应用70多年，安全性已得到明显提升，且已经广泛应用于重症患者凝血功能障碍或大出血的治疗，但若使用方法不当，可能会减弱止血效果或增加血栓形成的风险。为了规范PCC的合理使用，中国医药教育协会血栓与止血危重病专业委员会、全军重症医学专业委员会及中国研究型医院学会血栓与止血专业委员会组织制定此专家共识，包括定义、适应证、监测与评价等3个部分，共10条建议，旨在帮助临床医师合理使用PCC，以提高重症患者救治水平。

Abstract

The prothrombin complex concentrate (PCC) is a blood product that mainly contains vitamin K-dependent coagulation factors. PCC has been used clinically for more than 70 years, and its safety has been significantly improved. It has been widely used in the treatment of coagulation disorders or severe bleeding in critically ill patients. If used improperly, it may weaken the hemostatic effect or increase the risk of thrombosis. In order to standardize the rational use of PCC, Chinese Society of Thrombosis, Hemostasis and Critical Care, Chinese Medicine Education Association, People's Liberation Army Professional Committee of Critical Care Medicine, Chinese Society of Thrombosis and Hemostasis, Chinese Research Hospital Association have organized the formulation of this expert consensus, including three parts: definition, indications, and monitoring and evaluation of efficacy, with a total of 10 suggestions, aiming to help clinicians reasonably use PCC and improve the treatment in critical illness.

关键词

凝血酶原复合物血液凝固因子危重病出血

Keywords

prothrombin complex concentrateblood coagulation factorscritical illnesshemorrhage

references

Key NS, Negrier C. Coagulation factor concentrates: past, present, and future[J]. Lancet, 2007, 370(9585): 439-448.

Didisheim P, Loeb J, Blatrix C, et al. Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man[J]. J Lab Clin Med, 1959, 53(2): 322-330.

Tullis JL, Melin M, Jurigian P. Clinical use of human prothrombin complexes[J]. N Engl J Med, 1965,273(13):667-674.

Rosenberg PS, Goedert JJ. Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America[J]. Stat Med, 1998, 17(2): 155-168.

Suttie JW, McTigue J, Larson AE, et al. Biosynthesis of prothrombin complex proteins[J]. Ann N Y Acad Sci, 1981, 370: 271-280.

Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates[J]. Blood Transfus, 2009, 7(4): 325-334.

He XJ, Ma YF, Zhang GQ. Guidelines and consensus development standards and requirements for the Chinese Journal of Emergency Medicine[J]. Chin J Emer Med, 2021, 30(6): 661-662.

何小军, 马岳峰, 张国强. «中华急诊医学杂志»指南与共识制定规范与要求[J]. 中华急诊医学杂志, 2021, 30(6): 661-662.

Dahms SO, Demir F, Huesgen PF, et al. Sirtilins - the new old members of the vitamin K-dependent coagulation factor family[J]. J Thromb Haemost, 2019, 17(3): 470-481.

Burnouf T. Modern plasma fractionation[J]. Transfus Med Rev, 2007, 21(2): 101-117.

Brigulla M, Thiele T, Scharf C, et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates[J]. Transfusion, 2006, 46(3): 377-385.

Hoffman M, Monroe DM. Platelet binding and activity of recombinant factor VIIa[J]. Thromb Res, 2010, 125(Suppl 1): S16-S18.

Woodruff B, Sullenger B, Becker RC. Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?[J]. Curr Cardiol Rep, 2010, 12(4): 315-320.

Astermark J. Inhibitor development: patient-determined risk factors[J]. Haemophilia, 2010, 16(102): 66-70.

Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor[J]. Haemophilia, 2010, 12(s5): 4-13.

Curry B, Mueller S, MacLaren R. The use of prothrombin complex concentrates: results of a nationwide survey of critical care pharmacists[J]. J Pharm Pract, 2022, 35(2): 197-204.

Pagano MB, Foroutan F, Goel R, et al. Vitamin K antagonist reversal strategies: systematic review and network meta-analysis from the AABB[J]. Transfusion, 2022, 62(8): 1652-1661.

Ostermann H, von Heymann C. Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety[J]. Expert Rev Hematol, 2019, 12(7): 525-540.

Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage[J]. JAMA, 2015, 313(8): 824-836.

Margraf DJ, Brown SJ, Blue HL, et al. Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis[J]. BMC Emerg Med, 2022, 22(1): 14.

Nishijima DK, Dager WE, Schrot RJ, et al. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage[J]. Acad Emerg Med, 2010, 17(3): 244-251.

Spahn DR, Beer JH, Borgeat A, et al. NOACs in anesthesiology[J]. Transfus Med Hemother, 2019, 46(4): 282-293.

Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2016, 14(3): 623-627.

Frontera JA, 3rdLewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine[J]. Neurocrit Care, 2016, 24(1): 6-46.

Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways[J]. J Am Coll Cardiol, 2017, 70(24): 3042-3067.

Erdoes G, Martinez Lopez De Arroyabe B, Bolliger D, et al. International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery[J]. Anaesthesia, 2018, 73(12): 1535-1545.

Christensen H, Cordonnier C, Kõrv J, et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage[J]. Eur Stroke J, 2019, 4(4): 294-306.

Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy[J]. Blood Adv, 2018, 2(22): 3257-3291.

Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment[J]. J Thromb Thrombolysis, 2016, 41(1): 206-232.

Albaladejo P, Pernod G, Godier A, et al. Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016[J]. Anaesth Crit Care Pain Med, 2018, 37(4): 391-399.

Olivera P, Gabilondo M, Constans M, et al. Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants[J]. Med Clin (Barc), 2018, 151(5): 210.e1-210.e13.

Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios - is there a general consensus?[J]. Am J Emerg Med, 2020, 38(9): 1890-1903.

Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013[J]. Arch Cardiovasc Dis, 2013, 106(6-7):382-393.

Barnard LM, Guan S, Zarmer L, et al. Prehospital tourniquet use: an evaluation of community application and outcome[J]. J Trauma Acute Care Surg, 2021, 90(6): 1040-1047.

Friedman J, JrDitzel RM, Fisher AD. Coagulopathy associated with trauma: a rapid review for prehospital providers[J]. J Spec Oper Med, 2022, 22(2): 110-115.

Neeki MM, Dong FL, Toy J, et al. Tranexamic acid in civilian trauma care in the California prehospital antifibrinolytic therapy study[J]. West J Emerg Med, 2018, 19(6): 977-986.

Wong H, Curry N, Stanworth SJ. Blood products and procoagulants in traumatic bleeding: use and evidence[J]. Curr Opin Crit Care, 2016, 22(6): 598-606.

Obaid O, Anand T, Nelson A, et al. Fibrinogen supplementation for the trauma patient: should you choose fibrinogen concentrate over cryoprecipitate?[J]. J Trauma Acute Care Surg, 2022, 93(4): 453-460.

Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate[J]. Crit Care, 2010, 14(2): R55.

Ponschab M, Voelckel W, Pavelka M, et al. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma[J]. Scand J Trauma Resusc Emerg Med, 2015, 23: 84.

Rossaint R, Afshari A, Bouillon B, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition[J]. Crit Care, 2023, 27(1): 80.

Schöchl H, Voelckel W, Maegele M, et al. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients[J]. Crit Care, 2014, 18(4): R147.

Sniecinski RM, Levy JH. Bleeding and management of coagulopathy[J]. J Thorac Cardiovasc Surg, 2011, 142(3): 662-667.

Jimenez Rivera JJ, Iribarren JL, Raya JM, et al. Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study[J]. J Cardiothorac Surg, 2007, 2: 17.

Alwis S, Raja SG. Emergency cardiac surgery for patients on NOACs in the NOAC era - perspective[J]. Int J Surg, 2021, 87: 105893.

Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery[J]. Crit Care, 2016, 20: 5.

Hayes K, Fernando MC, Jordan V. Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding[J]. Cochrane Database Syst Rev, 2022, 11(11): CD013551

Smith MM, Schroeder DR, Nelson JA, et al. Prothrombin complex concentrate vs plasma for post-cardiopulmonary bypass coagulopathy and bleeding: a randomized clinical trial[J]. JAMA Surg, 2022, 157(9): 757-764.

Inaba K, Rizoli S, Veigas PV, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: Report of the panel[J]. J Trauma Acute Care Surg, 2015, 78(6):1220-1229.

Islam R, Kundu S, Jha SB, et al. Cirrhosis and coagulopathy: mechanisms of hemostasis changes in liver failure and their management[J]. Cureus, 2022, 14(4): e23785.

Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC Working Group on Hemostatic Management of Patients with Liver Disease[J]. J Thromb Haemost, 2021, 19(4): 1116-1122.

Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences[J]. Blood, 2010, 116(6): 878-885.

Drolz A, Horvatits T, Roedl K, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J]. Hepatology, 2016, 64(2): 556-568.

Chow JH, Lee K, Abuelkasem E, et al. Coagulation management during liver transplantation: use of fibrinogen concentrate, recombinant activated factor VII, prothrombin complex concentrate, and antifibrinolytics[J]. Semin Cardiothorac Vasc Anesth, 2018, 22(2): 164-173.

Biancofiore G, Blasi A, de Boer MT, et al. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE)[J]. Minerva Anestesiol, 2019, 85(7): 782-798.

van Dievoet MA, Stephenne X, Rousseaux M, et al. The use of prothrombin complex concentrate in chronic liver disease: a review of the literature[J]. Transfus Med, 2023, 33(3): 205-212.

Zamper RPC, Amorim TC, Queiroz VNF, et al. Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study[J]. BMC Anesthesiol, 2018, 18(1): 198.

Roberts LN, Lisman T, Stanworth S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2022, 20(1): 39-47.

O'Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis[J]. Gastroenterology, 2021, 161(5): 1615-1627.e1.

Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 73(1): 366-413.

Cho S, Perry AM, Cheng AM, et al. Advances in hemophilia A management[J]. Adv Pediatr, 2022, 69(1): 133-147.

Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review[J]. Biologics, 2021, 15: 221-235.

Brettler DB. Inhibitors in congenital haemophilia[J]. Baillieres Clin Haematol, 1996, 9(2): 319-329.

Zanon E. Acquired hemophilia A: an update on the etiopathogenesis, diagnosis, and treatment[J]. Diagnostics, 2023, 13(3): 420.

Godaert L, Bartholet S, Colas S, et al. Acquired hemophilia A in aged people: a systematic review of case reports and case series[J]. Semin Hematol, 2018, 55(4): 197-201.

Thrombosis and Hemostasis Group,Chinese Society of Hematology,Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the diagnosis and treatment of acquired hemophilia A (2021)[J]. Chin J Hematol, 2021, 42(10): 793-799.

中华医学会血液学分会血栓与止血学组,中国血友病协作组.获得性血友病A诊断与治疗中国指南(2021年版)[J].中华血液学杂志, 2021, 42(10):793-799.

Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients[J]. Haematologica, 2000, 85(10 Suppl): 15-20.

Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors[J]. Haemophilia, 1999, 5(Suppl 3): 25-32.

Hough RE, Hampton KK, Preston FE, et al. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors[J]. Br J Haematol, 2000, 111(3): 974-979.

Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association;Hemophilia Treatment Center Collaborative Network of China.Chinese guidelines on the treatment of hemophilia (version 2020) [J]. Chin J Hematol,2020,41(4):265-271.

中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 血友病治疗中国指南(2020年版) [J] . 中华血液学杂志, 2020, 41 (4): 265-271.

Kasper CK. Postoperative thromboses in hemophilia B[J]. N Engl J Med,1973, 289(3):160.

2ndWhite GC, Roberts HR, Kingdon HS, et al. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo[J]. Blood, 1977, 49(2): 159-170.

Köhler M. Thrombogenicity of prothrombin complex concentrates[J]. Thromb Res,1999, 95(4 Suppl 1): S13-S17.

Majeed A, Eelde A, Agren A, et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy[J]. Thromb Res, 2012, 129(2): 146-151.

Drebes A, de Vos M, Gill S, et al. Prothrombin complex concentrates for coagulopathy in liver disease: single-center, clinical experience in 105 patients[J]. Hepatol Commun, 2019, 3(4): 513-524.

Ghosh S, Krege W, Doerr B, et al. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models[J]. PLoS One, 2021, 16(10): e0258192.

Sørensen B, Spahn DR, Innerhofer P, et al. Clinical review: prothrombin complex concentrates: evaluation of safety and thrombogenicity[J]. Crit Care, 2011, 15(1): 201.

Sin JH, Berger K, Lesch CA. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: a retrospective evaluation[J]. J Crit Care, 2016, 36: 166-172.

Halbmayer WM. Rational, high quality laboratory monitoring before, during, and after infusion of prothrombin complex concentrates[J]. Thromb Res, 1999, 95(4 Suppl 1): S25-S30.

Elvstam O, Berntorp E, Schött U. ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy[J]. Scand J Clin Lab Invest, 2016, 76(3): 202-207.

Schneiderman J, Rubin E, Nugent DJ, et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience[J]. Haemophilia, 2007, 13(3): 244-248.

Scharbert G, Thaler U, Weilnböck C, et al. Heparin-induced effects of prothrombin complex concentrates in thromboelastometry[J]. Wien Klin Wochenschr, 2012, 124(9/10): 320-325.

Godier A, Greinacher A, Faraoni D, et al. Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2018, 16(1): 170-174.

Brackmann HH, Schramm W, Oldenburg J, et al. Origins, development, current challenges and future directions with activated prothrombin complex concentrate for the treatment of patients with congenital haemophilia with inhibitors[J]. Hamostaseologie, 2020, 40(5): 606-620.

Cao HJ, Tian Q, Huang Y, et al. Biochemical characterization of prothrombin complex concentrates in China[J]. Biologicals, 2015, 43(2): 84-91.

浏览量

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

循环线粒体DNA作为危重症预后的生物标记物:Meta分析与试验序贯分析

掌上超声对危重患者心功能评估的准确性研究

多腔道阻抗联合pH监测对危重症患者胃食管反流的诊断价值研究

电磁定位导航仪指导鼻空肠营养管置管的临床探索